Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
3.075 USD | +4.41% | +21.85% | -27.06% |
05-02 | CUREVAC : A missed opportunity | |
04-26 | UBS Cuts CureVac Price Target to $14 From $18, Maintains Buy Rating | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-27.06% | 660M | |
+19.75% | 46.81B | |
-0.62% | 41.37B | |
+47.07% | 41.29B | |
-3.52% | 28.87B | |
+11.98% | 26.06B | |
-19.55% | 19.13B | |
+33.33% | 12.39B | |
+0.28% | 12.08B | |
-0.08% | 11.96B |
- Stock Market
- Equities
- CVAC Stock
- News CureVac N.V.
- CureVac Starts Phase 1 Trial of COVID-19 Vaccine Candidate for Omicron Variant